Health ❯ Healthcare ❯ Pharmaceuticals ❯ Weight Loss

GLP-1 Drugs

Novo’s CagriSema Falls Short of Lilly’s Tirzepatide in 84-Week Head‑to‑Head Trial

The setback reinforces Lilly’s advantage — Novo now targets higher doses with an FDA decision expected late 2026.

Serena Williams’ Super Bowl Ro Ad Promotes GLP-1 Weight Loss, Draws Backlash

Hims & Hers Halts $49 Compounded Wegovy Pill as FDA Tightens GLP-1 Rules

Hims Launches $49 Compounded Wegovy-Style Pill as Novo Vows Legal Action

Jefferies Model Links GLP-1 Weight Loss Use to $580 Million in Annual Airline Fuel Savings

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

BMJ Review Flags Rapid Weight Regain After GLP‑1 Stop as UK Approves Higher‑Dose Wegovy

Novo Nordisk Launches Wegovy Weight‑Loss Pill in U.S. at $149 Starter Price

FDA Approves First Oral GLP-1 for Obesity as Novo’s Wegovy Pill Sets January U.S. Launch

FDA Approves Wegovy Weight-Loss Pill as First Oral GLP-1 for Obesity

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

WHO Endorses GLP‑1s for Obesity as Australia Adds Class‑Wide Mental Health Warning

Stopping GLP-1 Weight-Loss Drugs Before Pregnancy Linked to Higher Gestational Risks, Study Finds

U.S. Strikes Price-Cut Deals With Novo Nordisk and Eli Lilly for GLP‑1s, With Medicare Pilot in 2026

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Sam’s Club Joins Costco in Offering $499 Wegovy and Ozempic

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

ESC Data Tie Wegovy and Mounjaro to Lower HFpEF Hospitalization and Death, With Novo Citing CV Edge for Wegovy

Lilly’s Orforglipron Pill Hits Phase 3 Goals, Clearing Path to Global Filings

Serena Williams Discloses 31-Pound Loss With GLP-1, Goes Public With Ro Partnership